摘要
目的评价前列地尔对健康大鼠体内羟苯磺酸钙的药动学影响。方法 24只大鼠,按照体质量随机分为试验组和对照组,试验组按87.8 mg.kg-1剂量灌胃给予羟苯磺酸钙,并按11.7μg.kg-1剂量腹腔注射前列地尔,对照组按87.8 mg.kg-1剂量灌胃给予羟苯磺酸钙;采用HPLC法测定血药质量浓度,并用DAS 2.0软件计算药动学参数。结果试验组和对照组的主要药动学参数如下:AUC0-t为(210.73±50.71)、(201.79±45.29)μg.h.mL-1,MRT0-∞为(10.25±0.96)、(8.89±1.07)h,t1/2为(7.16±0.84)、(6.01±1.22)h,tmax为(1.58±0.29)、(2.67±0.49)h,CL为(0.40±0.10)、(0.42±0.09)L.h-1.kg-1,Cmax为(22.48±4.07)、(21.96±4.70)μg.mL-1。试验组的MRT0-∞、t1/2、tmax与对照组比较,差异均有统计学意义(P<0.05)。结论前列地尔可影响大鼠体内羟苯磺酸钙的代谢。
Objective To evaluate the effect of alprostadil on calcium dobesilate pharmacokinetic in rats.Methods 24 rats were divided into alprostadil group and control group by weight.Two groups were given calcium dobesilate of 87.8 mg·kg^-1 by po administration,espectively.The alprostadil group was given alprostadil of 11.7 μg·kg^-1 by intraperitoneal injection.The concentrations of calcium dobesilate were determined by HPLC.Pharmacokinetic parameters were calculated by using DAS 2.0 software.Results The main pharmacokinetic parameters of alprostadil group and control were as follows：AUC0-t was（210.73±50.71） and（201.79±45.29）μg·h·mL-1,MRT0-∞ was（10.25±0.96） and（8.89±1.07） h,t1/2 was（7.16±0.84） and（6.01±1.22） h,tmax was（1.58±0.29） and（2.67±0.49） h,CL was（0.40±0.10） and（0.42±0.09） L·h^-1·kg^-1,Cmax was（22.48±4.07） and（21.96±4.70） μg·mL^-1here were statistically significant difference in MRT0-∞,t1/2 and tmax between two groups（P0.05）.Conclusion Alprostadil can significantly affect the pharmacokinetics of calcium dobesilate in rats.
出处
《广东药学院学报》
CAS
2013年第1期12-15,共4页
Academic Journal of Guangdong College of Pharmacy
